ArticleFrontiers in nutrition2026
Triglyceride-glucose index, CKM stage, and absolute benefit of intensive blood pressure control: a
Article in Frontiers in nutrition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Intensive blood pressure control reduces cardiovascular events and all-cause mortality in SPRINT, but absolute benefit varies by baseline characteristics. The triglyceride-glucose (TyG) index may provide additional descriptive information within the cardiovascular-kidney-metabolic (CKM) staging framework. Methods: We performed a Results: Among 9,323 TyG-calculable participants, 8,036 were included in the main complete-case cohort; 1,282 remained unclassified by the CKM algorithm. Intensive blood pressure treatment reduced the primary composite outcome (HR 0.73, 95% CI 0.63-0.86) and all-cause death (HR 0.81, 95% CI 0.67-0.98). Formal testing showed nominal evidence that the treatment effect on all-cause death varied by TyG ( Conclusion: In SPRINT, TyG and CKM stage jointly described exploratory gradients in absolute benefit from intensive blood pressure treatment, particularly for all-cause death. Because analyses requiring CKM stage assignment excluded unclassified participants and formal interaction evidence was limited, these findings should be interpreted as hypothesis-generating absolute-risk stratification rather than as a treatment-selection rule.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.